title: Molecular basis of tetracycline action: identification of analogs whose primary target is not the bacterial ribosome.
abstract: Tetracycline analogs fell into two classes on the basis of their mode of action. Tetracycline, chlortetracycline, minocycline, doxycycline, and 6-demethyl-6-deoxytetracycline inhibited cell-free translation directed by either Escherichia coli or Bacillus subtilis extracts. A second class of analogs tested, including chelocardin, anhydrotetracycline, 6-thiatetracycline, anhydrochlortetracycline, and 4-epi-anhydrochlortetracycline, failed to inhibit protein synthesis in vitro or were very poor inhibitors. Tetracyclines of the second class, however, rapidly inhibited the in vivo incorporation of precursors into DNA and RNA as well as protein. The class 2 compounds therefore have a mode of action that is entirely distinct from the class 1 compounds, such as tetracycline that are used clinically. Although tetracyclines of the second class entered the cytoplasm, the ability of these analogs to inhibit macromolecular synthesis suggests that the cytoplasmic membrane is their primary site of action. The interaction of class 1 and class 2 tetracyclines with ribosomes was studied by examining their effects on the chemical reactivity of bases in 16S rRNA to dimethyl sulfate. Class 1 analogs affected the reactivity of bases to dimethyl sulfate. The response with class 2 tetracyclines varied, with some analogs affecting reactivity and others (chelocardin and 4-epi-anhydrotetracycline) not.
authors.affiliation: Infectious Disease/Molecular Biology Research Section, American Cyanamid, Lederle Laboratories, Pearl River, New York 10965.
authors.forename: B
authors.initials: B
authors.lastname: Rasmussen
authors.forename: H F
authors.initials: HF
authors.lastname: Noller
authors.forename: G
authors.initials: G
authors.lastname: Daubresse
authors.forename: B
authors.initials: B
authors.lastname: Oliva
authors.forename: Z
authors.initials: Z
authors.lastname: Misulovin
authors.forename: D M
authors.initials: DM
authors.lastname: Rothstein
authors.forename: G A
authors.initials: GA
authors.lastname: Ellestad
authors.forename: Y
authors.initials: Y
authors.lastname: Gluzman
authors.forename: F P
authors.initials: FP
authors.lastname: Tally
authors.forename: I
authors.initials: I
authors.lastname: Chopra
mesh_terms: D001419:Bacteria / Q000187:drug effects* / Q000648:ultrastructure; D001426:Bacterial Proteins / Q000096:biosynthesis; D003593:Cytoplasm / Q000187:drug effects / Q000378:metabolism; D004269:DNA, Bacterial / Q000096:biosynthesis; D005696:Galactosidases / Q000096:biosynthesis; D008566:Membranes / Q000187:drug effects; D010957:Plasmids; D014176:Protein Biosynthesis; D012329:RNA, Bacterial / Q000096:biosynthesis; D012335:RNA, Ribosomal / Q000096:biosynthesis; D012270:Ribosomes / Q000187:drug effects; D013754:Tetracyclines / Q000378:metabolism / Q000494:pharmacology*
chemical_list: D001426:Bacterial Proteins; D004269:DNA, Bacterial; D012329:RNA, Bacterial; D012335:RNA, Ribosomal; D013754:Tetracyclines; D005696:Galactosidases; C000400:chelocardin